Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Cullinan Therapeutics Inc (CGEM.O)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (US$) Price Target (US$) Rating
2021-08-2028.14-No Rating
2024-10-2315.6130.00Buy

Disclosures

  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
  • Because this security exhibits higher-than-average volatility, the FSR has been set at 25% above the MRA for a Buy rating, and at -25% below the MRA for a Sell rating (compared with 6/-6% under the normal rating system).
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.